Prognose
Analytikernes gennemsnitlige kursmål er 591,71 € (+6,29 %). Medianen er 613,34 € (+10,17 %).
| Køb |
4 |
| Behold |
15 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Medpace positions itself for AI revolution in the healthcare sector
The healthcare sector is seen as the next big market for AI, with Medpace and Thermo Fisher named as holdings in a US model portfolio. The biotech sector in particular stands to benefit, as AI identifies drug candidates more quickly, predicts protein structures, and makes therapies more targeted. This could turn early drug research from lengthy testing into a data-driven selection process. » Mere på finanzen.net
Medpace benefits from AI potential in biotech after strong second quarter
Medpace, a global contract research organization and full-service partner for clinical trials, reported an outstanding second quarter. The company provides study design, clinical monitoring, biostatistical analysis and integrated lab services and focuses on small and mid-sized biotech firms. Medpace is seen as a potential winner from AI adoption in biotechnology, as rising numbers of clinical trials could accelerate demand growth for its services. » Mere på finanzen.net
Medpace: revenue rises 17.2% in Q2, net order intake climbs 28.2% and full-year guidance up to $2.89 billion
Medpace reports revenue of $707.3 million (+17.2%) for the second quarter of 2026 and a 28.2% increase in net order intake, improving the predictability of its business base. The company confirms full-year guidance of up to $2.89 billion for 2026. The news triggered a roughly 16% jump in the share price, pushing the stock toward its all-time high. » Mere på finanzen.net
Medpace Holdings: record revenue, but weaker order intake dampens outlook
Medpace Holdings recorded record revenue but is facing a slower-than-expected order intake. The order volume is constraining growth prospects and could soften near-term revenue momentum. Investors and clients are now watching order intake developments and management’s response to the weak demand. » Mere på finanzen.net
Medpace reports strong Q1 growth, stock falls on weaker order dynamics
Medpace posted Q1 2026 revenue of $706.6 million and diluted EPS of $4.28, both above analysts' expectations, but reported a quarterly book-to-bill of 0.88 and higher cancellation rates. Backlog grew slightly to $2.93 billion, yet net new business lagged last year’s peak and the 2026 outlook signals a pronounced slowdown in growth. Despite strong cash generation and stable margins, pipeline risks and customer concentration drove a roughly 24% pre-market drop. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde Medpace en omsætning på 632,12 mio. € og et nettoresultat på 121,36 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 632,12 mio. | 12,41 % |
| Bruttofortjeneste | 197,66 mio. | 17,78 % |
| Nettoresultat | 121,36 mio. | 28,15 % |
| EBITDA | 156,69 mio. | 22,68 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 15,56 mia. € |
Antal aktier | 27,97 mio. |
Højeste/laveste i 52 uger | 632,45 € - 339,93 € |
| Udbytte | Nej |
Beta | 1,12 |
P/E (PE Ratio) | 33,25 |
PEG (PEG Ratio) | 1,32 |
K/I (PB Ratio) | 29,16 |
P/S (PS Ratio) | 6,02 |
Virksomhedsprofil
Medpace Holdings, Inc. leverer klinisk forskningsbaserede udviklingsydelser til lægemidler og medicinsk udstyr i Nordamerika, Europa og Asien. Virksomheden tilbyder en række ydelser, der understøtter den kliniske udviklingsproces fra Fase I til Fase IV inden for forskellige terapeutiske områder. Virksomheden leverer også kliniske udviklingsydelser til farmaceutisk industri, bioteknologisk industri og industrien for medicinsk udstyr; samt udformning af udviklingsplaner, koordineret centrallaboratorium, projektledelse, regulatoriske anliggender, klinisk monitorering, datahåndtering og -analyse, farmakovigilans, indsendelse af ansøgninger om godkendelse af nye lægemidler (NDA) og støtteydelser til klinisk opfølgning efter markedsføring. Derudover tilbyder virksomheden bioanalytiske laboratorieydelser, klinisk humanfarmakologi, billeddiagnostiske ydelser og støtte til aflæsning af elektrokardiogrammer til kliniske forsøg. Virksomheden blev grundlagt i 1992 og har hovedkvarter i Cincinnati, Ohio.
| Navn | Medpace |
| CEO | August James Troendle |
| Hjemsted | Cincinnati,
oh USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 11.08.2016 |
| Medarbejdere | 6.600 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | MEDP |
Frankfurt | 01P.F |
Düsseldorf | 01P.DU |
München | 01P.MU |